Publications by authors named "Mercy Mutambanengwe"
Unlabelled: HPTN 084 demonstrated the superiority of long-acting injectable cabotegravir (CAB-LA) compared with daily oral tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV prevention in women. CAB-LA (600 mg) or placebo injections were administered 4 weeks after an initial dose (loading dose) and every 2 months (Q2M) thereafter; this is the approved regimen. Participants experienced both loading dose and Q2M delays during the trial.
View Article and Find Full Text PDFArticle Synopsis
- Infants born to HIV-positive mothers in high tuberculosis regions are at risk for tuberculosis infection, and the study examines the effects of isoniazid preventive therapy initiated during pregnancy versus postpartum.
- The TB APPRISE trial was conducted across eight countries involving 956 mothers, comparing immediate isoniazid therapy during pregnancy to deferred therapy postpartum, and assessed the tuberculosis test results of their infants at 44 weeks.
- The analysis included 749 mother-infant pairs, aiming to evaluate the proportion of infants testing positive for tuberculosis and the predictors of positivity based on the timing of their mothers' isoniazid treatments.
Objectives: It is still unclear whether microwave ablation (MWA) outperforms radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC). Aim of this manuscript is to compare the two treatments through a meta-analysis of randomized-controlled trials (rcts).
Methods: Computerized bibliographic search was performed on main databases through August 2020.
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Clin Pharmacol Ther
April 2021
The World Health Organization guidelines recommend that individuals living with HIV receive ≥ 6 months of isoniazid preventive therapy, including pregnant women. Yet, plasma isoniazid exposure during pregnancy, in the antiretroviral therapy era, has not been well-described. We investigated pregnancy-induced and pharmacogenetic-associated pharmacokinetic changes and drug-drug interactions between isoniazid and efavirenz in pregnant women.
View Article and Find Full Text PDF